Ophthalmic surgery, lasers & imaging retina · 2026
Preoperative Intravitreal Viscoelastic Injection (PIVOT) for Surgical Optimization in Rhegmatogenous Retinal Detachment With Choroidal Detachment.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sahu Ritweez, Kumawat Devesh, Kaginalkar Ananya, Verma Saurabh, Azad Shorya Vardhan, Venkatesh Pradeep
Аннотация
BACKGROUND AND OBJECTIVE: Rhegmatogenous retinal detachment with choroidal detachment (RRDCD) is a challenging situation. This study evaluates the safety and efficacy of preoperative intravitreal viscoelastic injection (PIVOT) in facilitating vitrectomy in RRD-CD.
PATIENTS AND METHODS: This consecutive series included eight eyes of eight patients with RRD-CD (CD reaching to equator), managed between December 2024 and April 2025. Healon™ PRO (1% sodium hyaluronate) was injected intravitreally, typically one day prior to vitrectomy, along with topical difluprednate, cycloplegics, and oral corticosteroids. Outcome measures were intraocular pressure (IOP), cumulative CD height (by ultrasonography), injection-related adverse events, and intraoperative complications.
RESULTS: Mean IOP increased from 4.75 ± 2.05 mmHg at baseline to 10.0 ± 3.34 mmHg on day of surgery (P = .001). Cumulative CD reduced from 15.82 ± 4.88 mm to 5.49 ± 6.01 mm (P = .003). No adverse events were noted. Vitrectomy was safely completed, ensuring adequate silicone oil fill in all eyes.
CONCLUSION: PIVOT combined with anti-inflammatory treatment appears safe and effective in optimizing surgical conditions for RRD-CD.
PATIENTS AND METHODS: This consecutive series included eight eyes of eight patients with RRD-CD (CD reaching to equator), managed between December 2024 and April 2025. Healon™ PRO (1% sodium hyaluronate) was injected intravitreally, typically one day prior to vitrectomy, along with topical difluprednate, cycloplegics, and oral corticosteroids. Outcome measures were intraocular pressure (IOP), cumulative CD height (by ultrasonography), injection-related adverse events, and intraoperative complications.
RESULTS: Mean IOP increased from 4.75 ± 2.05 mmHg at baseline to 10.0 ± 3.34 mmHg on day of surgery (P = .001). Cumulative CD reduced from 15.82 ± 4.88 mm to 5.49 ± 6.01 mm (P = .003). No adverse events were noted. Vitrectomy was safely completed, ensuring adequate silicone oil fill in all eyes.
CONCLUSION: PIVOT combined with anti-inflammatory treatment appears safe and effective in optimizing surgical conditions for RRD-CD.